Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Dexmedetomidina y agitación después de la cirugía nasal

26 de septiembre de 2026 actualizado por: Yasser S Mostafa, MD, Fayoum University Hospital

Efectividad del bolo único versus la infusión continua de dexmedetomidina en la agitación mitigante en adultos sometidos a cirugía nasal: un ensayo prospectivo aleatorizado

The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.

Descripción general del estudio

Descripción detallada

Agitation during emergence from general anesthesia is a potentially serious phenomenon that has not been studied in adults as often as in pediatric population. When agitation, serious self-injury, or violence towards the medical team occur, with the risk of aspiration, bleeding, hypoxia, arrhythmias, or simply pulling the endotracheal tubes, removal of drains or catheters. Moreover, agitated patients are not only at risk of developing complications but also, they are labor intensive as they require more medical attention, rescue drugs, and more attending staff till agitation attack safely subside. Recognized risk factors to develop emergence agitation (EA) in adults include ear, nose, and throat surgery, obesity, sevoflurane anesthesia, endotracheal tube, and history of psychological illness. In adults, adjuvants have been co-administered with general anesthesia in order to negate or reduce the incidence of EA especially in patients with identified risk factors.

dexmedetomidine is a highly selective α2 sympatholytic, has been proposed as an attractive candidate for the prophylaxis of EA. By interacting with α2 receptors in locus coeruleus of the pons, Dex exerts its unique anxiolytic, sedative and sympathetic antagonistic action with no respiratory depression. Moreover, it has pain-modulating effect due to interaction with α2 receptor sites in the dorsal horn and supra-spinal regions.

Nevertheless, there have been conflicting data about Dex optimal dose and time of administration when used as prophylaxis against EA. Indeed, different dosing protocols are associated with over sedation, prolonged extubation time, and delayed post-anaesthesia care unit time.

No premedication. Basic general anesthesia monitoring included electrocardiogram, pulse oximetry, non-invasive arterial pressure, and capnography, were recorded every 5 min. Preoxygenation with 100% oxygen for 5 min was performed before fentanyl 1 μg/kg and propofol 1.5-2 mg/ kg, were administered as induction agents. Intubation with facilitated with atracurium besylate 0.5 mg/ kg. The size of endotracheal tubes was 6.5-7.5 mm, for females and males, respectively. Mechanical ventilation was set on 6 ml/kg tidal volume, and respiratory rate was adjusted to keep end-tidal CO2 between 35 and 40 mmHg, in 50% O2/air. All patients at induction were given dexamethasone 4 mg i.v., ondansetron, 4 mg i.v to prevent post-operative nausea and vomiting, plus Ringers lactate solution 6 mg/ kg drip for basic volume maintenance. Blood loss was compensated for with Ringers lactate, intraoperatively. Maintenance of anesthesia was carried out with Isoflurane, regulated at 2-3%, Titrated incremental doses of atropine 0.5 mg, esmolol 10 mg, and ephedrine 6 mg were given i.v., when HR ≤ 45, HR ≥ 120 and MAP ≤ 60, in the mentioned order. ketorolac 30 mg was given I.M., at the time of nasal packing.

When surgery was finished, gentle suction was attempted, non-depolarizing muscle relaxant reverse with atropine, 0.5 mg and neostigmine 0.02 mg/kg was given. Next, isoflurane was turned off and respiration was then converted back to manual ventilation with 100% oxygen at 7 L/min. The patients were not disturbed, except by continual verbal requests to open their eyes. All other stimuli were prevented. Extubation was done when patients were able to breathe spontaneously and interact with verbal demands. When patients were awake, calm, and sedated, they were transferred to the PACU. Patients were discharged from the PACU when their Aldrete score was ≥ 9.

Statistical analysis:

Statistical analysis will be conducted using IBM SPSS Statistics 22 (IBM Corporation, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p < 0.05 will be deemed to be statistically significant.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

50

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yasser S Mostafa, MD
  • Número de teléfono: +2 01010509735
  • Correo electrónico: ysm03@fayoum.edu.eg

Copia de seguridad de contactos de estudio

  • Nombre: Mohamed A Shawky, MD
  • Número de teléfono: +2 0 109 525 4547
  • Correo electrónico: mas14@fayoum.edu.eg

Ubicaciones de estudio

    • Faiyum Governorate
      • Al Fayyum, Faiyum Governorate, Egipto, 63514
        • Reclutamiento
        • Fayoum University Hospital
        • Contacto:
          • Yasser S Mostafa, MD.
          • Número de teléfono: +2 01010509735
          • Correo electrónico: ysm03@fayoum.edu.eg
        • Contacto:
          • Mohamed A Shawky, MD
          • Número de teléfono: +2 01095254547
          • Correo electrónico: mas14@fayoum.edu.eg

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 50 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • American Society of Anesthesiologist (ASA) Ⅰ or II
  • Adults with body mass index (BMI) < 30 Kg/m
  • Underwent elective nasal surgery.

Exclusion Criteria:

  • Significant comorbidity like hepatic, renal, or cardiac disease
  • Auditory impairment
  • Cognitive dysfunction
  • Substance abuse
  • Allergy to the studied medicines
  • Planned intensive care admission after the surgery.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Bolus group

single dose 0.5 µg/kg in 15 ml saline over 10 min , started 15 minutes before end of surgery

An infusion given all through intraoperative time

Otros nombres:
  • Infusión de dexmedetomidina
Experimental: Infusion group

Infusion of dexmedetomidine at a dose of 0.5 µg/kg/h without loading dose all through intraoperative time

Single dose given 15 minutes before end of surgery

Otros nombres:
  • Dexmedetomidina bolo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Degree of emergence agitation by Richmond Agitation Sedation Scale (RASS)
Periodo de tiempo: 5 minutes after operation

RASS is a 10-point scoring system used to assess patient's level of agitation and sedation: 4 levels for agitation, 1 level for normal (alert and calm), and 5 levels of sedation

5 minutes after operation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Intraoperative heart rate
Periodo de tiempo: Every 15 minutes along operation

Beats / minute

Every 15 minutes along operation
Intraoperative mean arterial blood pressure
Periodo de tiempo: Every 15 minutes along operation

mmHg

Every 15 minutes along operation
Time of first rescue analgesic
Periodo de tiempo: 5 minutes before first analgesic request

in minutes in minutes

5 minutes before first analgesic request
Extubation time
Periodo de tiempo: 3 minutes after removal of endotracheal tube

time interval between shutting off anesthetics to extubation (in minutes)

3 minutes after removal of endotracheal tube
Postanesthesia care unit time
Periodo de tiempo: 5 minutes after discharge from recovery unit

time interval from admission to PACU till patient scored ≥ 9 on Aldrete scale (ready to discharge)

5 minutes after discharge from recovery unit
Incidence of use of midazolam
Periodo de tiempo: 2 minutes after occurence of emergence agitation

Yes or no

2 minutes after occurence of emergence agitation
Numerical rating score (NRS)
Periodo de tiempo: Every 10 min in postanesthesia care unit

10 point scale where zero meaning "no pain" and 10 meaning "the worst pain imaginable"

Every 10 min in postanesthesia care unit
Total amount of rescue analgesic
Periodo de tiempo: 24 hours postoperative

in milligram

24 hours postoperative
Boezaart Surgical Field Grading Scale
Periodo de tiempo: 2 hours intraoperatively

endoscopically using the six-point score (0-5 Scale) where 0 - No bleeding, 1 - Slight bleeding, no suctioning needed, 2 - Slight bleeding, occasional suctioning needed, 3 - Moderate bleeding, frequent suctioning needed, visibility maintained, 4 - Heavy bleeding, constant suctioning needed, visibility impaired, 5 - Severe bleeding, uncontrolled, surgery impossible

2 hours intraoperatively
Incidence of bradycardia
Periodo de tiempo: 2 hours intraoperatively

Yes or no

2 hours intraoperatively
Incidence of hypotension
Periodo de tiempo: 2 hours intraoperatively

Yes or no when mean arterial blood pressure below 60 mmHg

2 hours intraoperatively
Incidence of nausea
Periodo de tiempo: 24 hours postoperative

Yes or no

24 hours postoperative
Incidence of vomiting
Periodo de tiempo: 24 hours postoperative

Yes or no

24 hours postoperative

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Age
Periodo de tiempo: 5 minutes before entering operation department

in years

5 minutes before entering operation department
Sex
Periodo de tiempo: 5 minutes before entering operation department

Male of female

5 minutes before entering operation department
Weight
Periodo de tiempo: 5 minutes before entering operation department

In kilogram

5 minutes before entering operation department
Height
Periodo de tiempo: 5 minutes before entering operation department

In centimeter

5 minutes before entering operation department
Duration of surgery
Periodo de tiempo: 5 minutes after end of surgery

In minutes

5 minutes after end of surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Yasser S Mostafa, MD, Fayoum University
  • Silla de estudio: Mohamed A Shawky, MD, Fayoum University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de agosto de 2025

Finalización primaria (Estimado)

1 de noviembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

4 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

5 de marzo de 2025

Publicado por primera vez (Actual)

10 de marzo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir